Arca
Skip to content

Ankylosing spondylitis

Drug research and approvals for ankylosing spondylitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 50 studies of ankylosing spondylitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 50
  • Trials authorized in Canada: 13
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 50 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 13; search them all in Canada trials
Aug 13, 2025A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with radiographic axial…TULISOKIBART (MK-7240)Merck & Co. (MSD)Ongoing
Sep 3, 2021A phase 2 multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to evaluate the efficacy and safety of cc-99677 in subjects with…BMS-986371 (CC-99677)Bristol-Myers SquibbClosed
Aug 31, 2020A phase 3, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of filgotinib in subjects with active ankylosing spondylitis…FILGOTINIBGilead SciencesClosed
Aug 31, 2020A phase 3, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of filgotinib in subjects with active ankylosing spondylitis…FILGOTINIBGilead SciencesClosed
Apr 23, 2018A phase 3, randomized, double-blind, placebo-controlled, study of the efficacy and safety of tofacitinib in subjects with active ankylosing spondylitis (as)TOFACITINIB (CP-690,550)PfizerClosed
Nov 14, 2017A multicenter, open-label, extension study to evaluate the long term safety and efficacy of bimekizumab in subjects with ankylosing spondylitisBIMEKIZUMABUCBOngoing
Nov 10, 2017A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus gp2017…COSENTYX / GP2017 (ADALIMUMAB)Novartis Pharmaceuticals CorporationClosed
Aug 14, 2017A multicenter, randomized, double-blind, placebo controlled study evaluating the safety and efficacy of upadacitinib in subjects with active ankylosing…UPADACITINIB (ABT-494)AbbVieClosed
Nov 23, 2016A multicenter, phase 2b, randomized, double blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of bimekizumab in…BIMEKIZUMABUCBOngoing
Feb 13, 2015A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading…SECUKINUMAB (AIN457)Novartis Pharmaceuticals CorporationOngoing

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
May 18, 2018Zesslyinfliximab · biosimilarSandoz GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.